The many strategies for functionalizing C=C and C-H bonds that have evolved in Nature have captivated the imaginations of chemists and form the foundation of biomimetic chemistry (1, 2). The reverse of this, using inspiration from synthetic chemistry to discover and develop new biocatalysts, is a nascent frontier in molecular engineering whose recent highlights include C-H activation by artificial rhodium enzymes (3) and the de novo design of Diels-Alderases (4). Synthetic chemists have developed powerful methods for direct C=C and C-H functionalization based on transition metal-catalyzed carbenoid and nitrenoid transfers, reactions that are widely used to synthesize natural product intermediates and pharmaceuticals (5). The asymmetric cyclopropanation of olefins with high-energy carbene precursors (e.g., acceptor-substituted diazo reagents) is a hallmark reaction that generates up to 3 stereogenic centers in a single step to make the important cyclopropane motif, featured in many natural products and therapeutic agents (6). Limited to using physiologically accessible reagents, Nature catalyzes intermolecular cyclopropane formation through wholly different strategies, typically involving olefin addition to the methyl cation of S-adenosyl methionine or through cyclization of dimethylallyl pyrophosphate-derived allylic carbenium ions (7). As a result, the diverse cyclopropanation products that can be formed by metallocarbene chemistry cannot be readily accessed by engineering natural cyclopropanation enzymes. We hypothesized that a natural metalloenzyme, the iron-heme-containing cytochrome P450, could be engineered to catalyze formal carbenoid transfers, thereby combining the high levels of regio-and stereoselectivity of enzymes with the synthetic versatility of carbenebased strategies.
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Members of the cytochrome P450 enzyme family catalyze myriad oxidative transformations, including hydroxylation, epoxidation, oxidative ring coupling, heteroatom release, and heteroatom oxygenation (8) . Most transformations encompassed by this broad catalytic scope manifest the reactivity of the same high-valent iron-oxene intermediate, Compound I (Fig. 1) . Inspired by the impressive chemo-, regio-and stereoselectivities with which cytochrome P450s can insert oxygen atoms into C-H and C=C bonds, we investigated whether these enzymes could be engineered to mimic this chemistry for isoelectronic carbene transfer reactions via a high-valent iron-carbenoid species (Fig. 1) . Here we report that variants of the cytochrome P450 from Bacillus megaterium (CYP102A1, or P450 BM3 ) are efficient catalysts for the asymmetric metallocarbene-mediated cyclopropanation of styrenes.
Because iron porphyrins catalyze carbene-based cyclopropanations (9, 10), we first probed whether some common heme proteins display measurable levels of cyclopropanation activity in aqueous media (phosphate buffer, 5% methanol co-solvent). We chose the reaction between styrene and ethyl diazoacetate (EDA, Fig. 2 ), a well-recognized model system for validating new cyclopropanation catalysts. Initial experiments showed that optimal formation of the desired cyclopropanation products occurred in the presence of a reducing agent (e.g., sodium dithionite, Na 2 S 2 O 4 ) under anaerobic conditions (tables S1 to S4). Horseradish peroxidase (HRP), cytochrome c (cyt c), myoglobin (Mb) and P450 BM3 all displayed multiple turnovers toward the cyclopropane products, with HRP, cyt c and Mb showing negligible enantioinduction and formed the trans cyclopropane with over 90% diastereoselectivity, which is comparable to the diastereoselectivity induced by free hemin (table S1). P450 BM3 , despite forming the cyclopropane products in low yield, catalyzed the reaction with different diasteroselectivity (cis: trans 37: 63) and slight enantioinduction ( Table 1) , showing that carbene transfer and selectivity are dictated by the heme cofactor bound in the enzyme active site.
We then explored whether the activity and selectivity of hemecatalyzed cyclopropanation could be enhanced by engineering the protein sequence. P450 BM3 is a well-studied, soluble, self-sufficient (heme and diflavin reductase domains are fused in a single polypeptide, ~120 KDa), long-chain fatty acid monooxygenase. More than a decade of protein engineering attests to the functional plasticity of this biocatalyst (11) . From our work using directed evolution to engineer cytochrome P450 BM3 for synthetic applications we have accumulated thousands of variants that exhibit monooxygenase activity on a wide range of substrates (12) . We tested some of these variants for altered cyclopropanation diastero-and enantioselectivity by analysis of product distributions using gas chromatography (GC) with a chiral stationary phase. A panel of 92 P450 BM3 variants, chosen for diversity of activity and protein sequence, was screened in E. coli lysate for the reaction of styrene and EDA under aerobic conditions in the presence of Na 2 S 2 O 4 (tables S5 and S6). The ten most promising hits were selected for purification and characterization under standardized anaerobic reaction conditions (Table 1 and table S7) .
Five of the ten selected P450s showed improvements in activity compared to wild type (total turnover numbers (TTN) > 100), a comprehensive range of diastereoselectivities with cis: trans ratios varying from 9: 91 to 60: 40, and up to 95% enantioselectivities ( We used H2A10 to verify the role of the enzyme in catalysis and identify optimal conditions (table S8 and figs. S1 and S2). Heat inactivation produced diastereo-and enantioselectivities similar to those obtained with free hemin, consistent with protein denaturation and release of the cofactor. Complete inhibition was achieved by pre-incubating the reaction mixture with carbon monoxide, which irreversibly binds the reduced P450 heme, confirming that catalysis occurs at the active site. Air inhibited the cyclopropanation reaction by about 50%, showing that dioxygen and EDA compete for reduced Fe II . Cyclopropanation was also achieved with NADPH as the reductant, confirming that the activity can also be driven by the endogenous electron transport machinery of the diflavin-containing reductase domain. The presence of a reducing agent in sub-stoichiometric amounts proved essential for cyclopropanation (table S9), implying that the active species is Fe II rather than the resting state Fe III . Highly active P450 BM3 variants H2A10, H2-5-F10 and H2-4-D4 have three to five active site alanine substitutions with respect to 9-10A-TS-F87V (12 mutations from P450 BM3 , Supporting Online Material text), which itself shows negligible cyclopropanation activity. These variants exhibit a range of TTN, diastereoselectivity, and enantioselectivity (Table 1). To better understand how protein sequence controls P450-mediated cyclopropanation, we constructed 12 variants to assess the contributions of individual alanines to catalysis and stability [table S10 (13) ]. T268A is key for achieving high cyclopropanation activity, and this mutation alone converts inactive 9-10A-TS-F87V into an active cyclopropanation catalyst. Variant 9-10A-TS-F87V-T268A (here called BM3-CIS) is a competent cyclopropanation catalyst (199 TTN), displays strong preference for the cis product (cis: trans 71: 29), forms both diastereomers with over 90% ee, and is as stable as wild-type P450 BM3 . Other active site alanine mutations tune the product distribution. Notably, the addition of I263A to BM3-CIS reverses diastereoselectivity (cis: trans 19: 81). We also investigated the effects of similar mutations introduced in the poorly active wild type P450 BM3 (table S11) . Impressively, P450 BM3 -T268A, with a single mutation, is an active cyclopropanation catalyst (323 TTN, Table 1 ) with exquisite transselectivity (cis: trans 1: 99) and high enantioselectivity for the major diastereomer (-96% ee trans , Fig. 1 ). Whereas BM3-CIS is a cis-selective cyclopropanation catalyst, identical active site mutations in wild type P450 BM3 result in a trans-selective enzyme (table S11), demonstrating that mutations outside of the active site also influence the stereochemical outcome.
Because the design of cis-selective small-molecule catalysts for diazocarbonyl-mediated cyclopropanations has proven more challenging than their trans counterparts (14), we investigated whether active site engineering of P450 BM3 could provide robust cis-selective watercompatible catalysts to complement existing organometallic systems (15) . We chose five active site residues (L181, I263, A328, L437, T438) for individual site-saturation mutagenesis (13) . The A328G, T438A, T438S and T438P variants exhibited enhanced cis-selectivity (table  S12) . Notably A328G also reversed the enantioselectivity for the cisdiastereomer (Table 1) . BM3-CIS-T438S displayed the highest diastereo-and enantioselectivities (cis: trans 92: 8 and -97% ee cis ) and maintained TTN comparable to BM3-CIS (Table 1) .
BM3-CIS exhibits Michaelis-Menten kinetics ( fig. S3 and table S13) with relatively high K M values for the olefin (~1.5 mM) and the diazoester (~5 mM), reflecting the lack of evolutionary pressure for this enzyme to bind these substrates. BM3-CIS exhibits a notable k cat for cyclopropanation of 100 min −1 , comparable to the k cat of many native P450s for hydroxylation, but about fifty times less than P450 BM3 -catalyzed fatty acid hydroxylation (table S14). Free hemin does not exhibit saturation kinetics and displays slower initial rates than BM3-CIS (only 30 min −1 at 10 mM styrene and 15 mM EDA), indicating that the protein scaffold enhances k cat compared to the free cofactor in solution. When used at 0.2 mol% equivalent, BM3-CIS-catalyzed cyclopropanations reached completion after 30 min. Adding more EDA enhanced turnovers for cyclopropanes and preserved BM3-CIS stereoselectivity (table S15), confirming catalyst integrity and implying that the reaction stops because of EDA depletion rather than inactivation.
To assess the substrate scope of P450 BM3 -catalyzed cyclopropanation, we investigated the activities of six variants against a panel of olefins and diazo compounds ( Table 2 and tables S16-S20). P450 cyclopropanation is robust to both electron-donating (pvinylanisole, p-vinyltoluene) and electron-withdrawing (ptrifluoromethylstyrene) substitutions on styrene, and variant 7-11D showed consistent cis-selectivity for these substrates. The P450s were also active on 1,1-disubstituted olefins (i.e., α-methyl styrene), with chimeric P450 C2G9R1 forming cyclopropanes in 77% yield (with respect to EDA). The P450s were only moderately active with t-butyl diazoacetate as substrate (<30% yield), forming the trans product with >87% selectivity and offering no advantage over free hemin (table S20) . For reactions involving EDA and aryl-substituted olefins, however, the P450s consistently outperformed the free cofactor in both activity and stereoselectivity.
Screening natural enzymes against synthetic reagents chosen based on chemical intuition offers a simple strategy for identifying enzymes with basal levels of non-native activity. As we have shown, a single mutation can be enough to promote such activity and achieve synthetically useful stereoselectivities. Accumulation of beneficial mutations by directed evolution or other protein engineering strategies can generate a spectrum of highly active catalysts for desired substrate and product specificities. The established reaction promiscuity of natural enzymes (16, 17) and the surprising ease with which cyclopropanation activity could be installed into P450 BM3 suggest that this approach will be useful for other synthetically important transformations for which biological counterparts do not yet exist. 
